Synergic Effect of Early Administration of Probiotics and Adipose-Derived Mesenchymal Stem Cells on Alleviating Inflammation-Induced Chronic Neuropathic Pain in Rodents
Overview
Chemistry
Molecular Biology
Authors
Affiliations
This study investigated the hypothesis that probiotics enhanced the therapeutic effect of adipose-derived mesenchymal stem cells (ADMSCs) on alleviating neuropathic pain (NP) due to chronic constriction injury (CCI) mainly through regulating the microbiota in rats. SD rats (n = 50) were categorized into group 1 (sham-control), group 2 (NP), group 3 (NP + probiotics (i.e., 1.5 billion C.F.U./day/rat, orally 3 h after NP procedure, followed by QOD 30 times)), group 4 (NP + ADMSCs (3.0 × 105 cells) 3 h after CCI procedure, followed by QOD six times (i.e., seven times in total, i.e., mimic a clinical setting of drug use) and group 5 (NP + probiotics + ADMSCs (3.0 × 105 cells)) and euthanized by day 60 after NP induction. By day 28 after NP induction, flow-cytometric analysis showed circulating levels of early (AN-V+/PI−) and late (AN-V+/PI+) apoptotic, and three inflammatory (CD11b-c+, Ly6G+ and MPO+) cells were lowest in group 1 and significantly progressively reduced in groups 2 to 5 (all p < 0.0001). By days 7, 14, 21, 28, and 60 after CCI, the thresholds of thermal paw withdrawal latency (PWL) and mechanical paw withdrawal threshold (PWT) were highest in group 1 and significantly progressively increased in groups 2 to 5 (all p < 0.0001). Numbers of pain-connived cells (Nav1.8+/peripherin+, p-ERK+/peripherin+, p-p38+/peripherin+ and p-p38+/NF200+) and protein expressions of inflammatory (p-NF-κB, IL-1ß, TNF-α and MMP-9), apoptotic (cleaved-caspase-3, cleaved-PARP), oxidative-stress (NOX-1, NOX-2), DNA-damaged (γ-H2AX) and MAPK-family (p-P38, p-JNK, p-ERK1/2) biomarkers as well as the protein levels of Nav.1.3, Nav.1.8, and Nav.1.9 in L4-L5 in dorsal root ganglia displayed an opposite pattern of mechanical PWT among the groups (all p < 0.0001). In conclusion, combined probiotic and ADMSC therapy was superior to merely one for alleviating CCI-induced NP mainly through suppressing inflammation and oxidative stress.
Advances and challenges in cell therapy for neuropathic pain based on mesenchymal stem cells.
Zhang W, Pi X, Hu D, Liu X, Wu M Front Cell Dev Biol. 2025; 13:1536566.
PMID: 40061013 PMC: 11885280. DOI: 10.3389/fcell.2025.1536566.
Chen H, Luo C, Chen Y, Chiang J, Huang C, Wang Y Int J Biol Sci. 2024; 20(15):6162-6180.
PMID: 39664585 PMC: 11628340. DOI: 10.7150/ijbs.101051.
DSouza R, Her Y, Hussain N, Karri J, Schatman M, Calodney A J Pain Res. 2024; 17:2951-3001.
PMID: 39282657 PMC: 11402349. DOI: 10.2147/JPR.S480559.
Microbiome contributions to pain: a review of the preclinical literature.
Pratt M, Plumb A, Manjrekar A, Cardona L, Chan C, John J Pain. 2024; 166(2):262-281.
PMID: 39258679 PMC: 11723818. DOI: 10.1097/j.pain.0000000000003376.
Pathology of pain and its implications for therapeutic interventions.
Cao B, Xu Q, Shi Y, Zhao R, Li H, Zheng J Signal Transduct Target Ther. 2024; 9(1):155.
PMID: 38851750 PMC: 11162504. DOI: 10.1038/s41392-024-01845-w.